Aralez Pharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total revenue of $12,578,000 compared to $5,201,000 a year ago. Loss before income taxes was $17,984,000 compared to $15,279,000 a year ago. Net loss was $17,475,000 or $0.27 per diluted common share compared to $16,280,000 or $0.50 per basic and diluted common share a year ago. Loss from operations was $17,121,000 compared to $15,294,000 a year ago. For the six months, the company reported total revenue of $20,635,000 compared to $9,605,000 a year ago. Loss before income taxes was $51,118,000 compared to $15,307,000 a year ago. Net loss was $51,263,000 or $0.96 per diluted common share compared to $16,308,000 or $0.50 per basic and diluted common share a year ago. Loss from operations was $54,745,000 compared to $15,136,000 a year ago.